Bayforest Capital’s 10x Genomics TXG Stock Holding History

Bayforest Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5,788	Closed	-$222K	–	1204
2026 Q2	$222K	Buy	5,788 +5,246	+968%	+$137K	0.21%	144
2026 Q1	$11.5K	Sell	542 -16,983	-97%	-$340K	0.01%	783
2025 Q4	$286K	Sell	17,525 -54,302	-76%	-$820K	0.21%	157
2025 Q3	$840K	Sell	71,827 -23,037	-24%	-$300K	0.4%	33
2025 Q2	$1.1M	Buy	94,864 +69,306	+271%	+$632K	0.48%	25
2025 Q1	$223K	Buy	25,558 +16,540	+183%	+$208K	0.1%	368
2024 Q4	$129K	Buy	+9,018	New	+$142K	0.16%	243

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

Bayforest Capital's TXG Position: Q3 2026 in Review

Bayforest Capital sold out of 10x Genomics (TXG) in Q3 2026, closing a stake of 5,788 shares — an estimated $222K sold.

Bayforest Capital first reported a position in TXG in Q4 2024 and held it in 7 quarters. The position peaked at $1.1M in Q2 2025. 257 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

Bayforest Capital reported no remaining 10x Genomics position as of Q3 2026 after selling out during the quarter.
Bayforest Capital sold 5,788 10x Genomics shares in Q3 2026, an estimated $222K.
Bayforest Capital first reported a position in 10x Genomics in Q4 2024 and held it in 7 quarters.
Bayforest Capital's 10x Genomics position peaked at $1.1M in Q2 2025.
257 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Bayforest Capital's 13F filing for Q3 2026, filed 3 Nov 2026.